RS52663B2 - Nova kristalna forma tiotropijum bromida i proces njene pripreme - Google Patents

Nova kristalna forma tiotropijum bromida i proces njene pripreme

Info

Publication number
RS52663B2
RS52663B2 RS20120583A RSP20120583A RS52663B2 RS 52663 B2 RS52663 B2 RS 52663B2 RS 20120583 A RS20120583 A RS 20120583A RS P20120583 A RSP20120583 A RS P20120583A RS 52663 B2 RS52663 B2 RS 52663B2
Authority
RS
Serbia
Prior art keywords
tiotropium bromide
crystalline
contain
preparation
crystalline form
Prior art date
Application number
RS20120583A
Other languages
English (en)
Serbian (sr)
Inventor
Nicola Diulgheroff
Francesca Scarpitta
Alessandro Pontiroli
Adrienne Kovacsne-Mezei
Judith Aronhime
Alexandr Jegorov
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38115166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52663(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of RS52663B publication Critical patent/RS52663B/sr
Publication of RS52663B2 publication Critical patent/RS52663B2/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20120583A 2005-12-19 2006-12-19 Nova kristalna forma tiotropijum bromida i proces njene pripreme RS52663B2 (sr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US75267205P 2005-12-19 2005-12-19
US75453005P 2005-12-27 2005-12-27
US76143706P 2006-01-23 2006-01-23
US77405106P 2006-02-15 2006-02-15
US78031006P 2006-03-07 2006-03-07
US83218906P 2006-07-20 2006-07-20
US85122306P 2006-10-12 2006-10-12
US85274006P 2006-10-18 2006-10-18
EP06847887.4A EP1869035B2 (en) 2005-12-19 2006-12-19 Novel crystalline form of tiotropium bromide and process for preparation thereof
PCT/US2006/048734 WO2007075858A2 (en) 2005-12-19 2006-12-19 Novel forms of tiotropium bromide and processes for preparation thereof

Publications (2)

Publication Number Publication Date
RS52663B RS52663B (sr) 2013-06-28
RS52663B2 true RS52663B2 (sr) 2018-05-31

Family

ID=38115166

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120583A RS52663B2 (sr) 2005-12-19 2006-12-19 Nova kristalna forma tiotropijum bromida i proces njene pripreme

Country Status (17)

Country Link
US (4) US8163913B2 (enExample)
EP (2) EP2123650B1 (enExample)
JP (3) JP5086267B2 (enExample)
KR (1) KR101395881B1 (enExample)
CN (1) CN102731494A (enExample)
AT (1) ATE552256T1 (enExample)
BR (1) BRPI0608427A2 (enExample)
CA (1) CA2627729A1 (enExample)
DK (1) DK1869035T4 (enExample)
ES (2) ES2384486T3 (enExample)
IL (1) IL187947A0 (enExample)
MX (1) MX2007009988A (enExample)
PL (2) PL2123650T3 (enExample)
PT (1) PT1869035E (enExample)
RS (1) RS52663B2 (enExample)
TW (1) TW200732340A (enExample)
WO (1) WO2007075858A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1869035T4 (en) * 2005-12-19 2015-11-16 Sicor Inc HIS UNKNOWN CRYSTALLIC FORM OF THIOTROPIUM BROMIDE AND PROCEDURE FOR PREPARING THEREOF
US9108962B2 (en) * 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
ES2523695T3 (es) * 2008-01-10 2014-11-28 Generics [Uk] Limited Nuevo proceso para la preparación de ésteres de escopina
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
WO2010052466A2 (en) * 2008-11-04 2010-05-14 Cipla Limited Pharmaceutical aerosol composition
CA2742356A1 (en) * 2008-11-04 2010-05-14 Cipla Limited Tiotropium bromide having a low degree of crystallinity
CA2768553C (en) 2009-08-07 2016-08-02 Generics [Uk] Limited Anhydrate of tiotropium bromide
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
TR201111589A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür susuz kristal formu.
CZ304368B6 (cs) 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
HUE032455T2 (en) 2012-11-05 2017-09-28 Zentiva Ks Stabilization of thiotropium solvates
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
EP2789611A1 (en) * 2013-04-08 2014-10-15 Cerbios-Pharma S.A. A crystalline form of tiotropium bromide
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
RU2567539C1 (ru) * 2015-02-04 2015-11-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ (1α,2β,4β,5α,7β-7)-[(ГИДРОКСИДИ-2-ТИЕНИЛАЦЕТИЛ)ОКСИ]-9,9-ДИМЕТИЛ-3-ОКСА-9-АЗОНИАТРИЦИКЛО[3.3.1.02,4]НОНАН БРОМИДА МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
WO2017138896A1 (en) 2016-02-11 2017-08-17 Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti Crystalline form of tiotropium bromide anhydrate
WO2020013330A1 (ja) * 2018-07-13 2020-01-16 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
EP4108230A1 (en) 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US6736830B2 (en) 2000-08-22 2004-05-18 Deborah M. Roust Baby pacifier
TR200402367T4 (tr) * 2000-10-12 2004-12-21 Boehringer Ingelheim Pharma Gmbh& Co.Kg Yeni tiotropyum içeren inhalasyon tozları
OA12403A (en) 2000-10-12 2006-04-18 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament.
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE10064816A1 (de) * 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
EA005813B1 (ru) * 2001-06-22 2005-06-30 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Безводный кристаллический тиотропийбромид, способ его получения и его применение для получения лекарственного средства
US6890291B2 (en) 2001-06-25 2005-05-10 Mission Medical, Inc. Integrated automatic blood collection and processing unit
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
RU2005122444A (ru) 2002-12-16 2007-01-27 Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) Композиции в виде содержащих тиотропий растворов с гидрофторуглеродом
UA83813C2 (ru) * 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
DE10351196B4 (de) 2003-10-28 2016-08-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung einer anodisch mit Silizium bondbaren Glas-Keramik (LTCC)
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SI2067779T1 (sl) 2003-11-03 2013-08-30 Boehringer Ingelheim International Gmbh Tiotropijeve soli, postopek za njihovo pripravo in formulacije zdravil, ki jih vsebujejo
JP5165245B2 (ja) * 2003-11-03 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なチオトロピウム塩、その製造方法及びチオトロピウム塩を含有する医薬組成物
BRPI0415636A (pt) * 2003-11-03 2006-12-12 Boehringer Ingelheim Int anidrato cristalino com efeito anticolinérgico
CN1271073C (zh) 2004-10-26 2006-08-23 江苏正大天晴药业股份有限公司 结晶性抗胆碱能药噻托溴铵晶体
EP1881980B1 (en) 2005-05-02 2012-08-22 Boehringer Ingelheim International GmbH Novel crystalline forms of tiotropium bromide
RU2007144531A (ru) 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые кристаллические формы тиотропийбромида
DK1869035T4 (en) * 2005-12-19 2015-11-16 Sicor Inc HIS UNKNOWN CRYSTALLIC FORM OF THIOTROPIUM BROMIDE AND PROCEDURE FOR PREPARING THEREOF
SI1869035T2 (sl) * 2005-12-19 2015-12-31 Sicor, Inc. Nove kristalne oblike tiotropij bromida in postopek njihove priprave
EP1923393A1 (en) 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
EP2020403A1 (en) * 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
CA2768553C (en) * 2009-08-07 2016-08-02 Generics [Uk] Limited Anhydrate of tiotropium bromide

Also Published As

Publication number Publication date
EP2123650B1 (en) 2012-04-04
KR101395881B1 (ko) 2014-05-21
US8163913B2 (en) 2012-04-24
JP5567610B2 (ja) 2014-08-06
WO2007075858A3 (en) 2007-11-01
BRPI0608427A2 (pt) 2009-12-29
JP5086267B2 (ja) 2012-11-28
RS52663B (sr) 2013-06-28
MX2007009988A (es) 2008-02-22
KR20080078779A (ko) 2008-08-28
ES2384486T3 (es) 2012-07-05
JP2012176975A (ja) 2012-09-13
US20120108625A1 (en) 2012-05-03
CN102731494A (zh) 2012-10-17
PL2123650T3 (pl) 2012-09-28
US8846926B2 (en) 2014-09-30
US20140057935A1 (en) 2014-02-27
US20120165364A1 (en) 2012-06-28
CA2627729A1 (en) 2007-07-05
JP2012136538A (ja) 2012-07-19
PL1869035T3 (pl) 2013-04-30
EP2123650A1 (en) 2009-11-25
ES2396978T5 (es) 2015-12-04
DK1869035T4 (en) 2015-11-16
WO2007075858A2 (en) 2007-07-05
EP1869035B2 (en) 2015-08-12
US20070225314A1 (en) 2007-09-27
PT1869035E (pt) 2013-01-10
ATE552256T1 (de) 2012-04-15
DK1869035T3 (da) 2013-01-14
TW200732340A (en) 2007-09-01
ES2396978T3 (es) 2013-03-01
JP2009513675A (ja) 2009-04-02
PL1869035T5 (pl) 2016-01-29
EP1869035A2 (en) 2007-12-26
IL187947A0 (en) 2008-03-20
EP1869035B1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
RS52663B2 (sr) Nova kristalna forma tiotropijum bromida i proces njene pripreme
JP2006526031A5 (enExample)
EP1802588A1 (en) Substituted amino-pyrimidones and uses thereof
HRP20250159T1 (hr) Kruti oblici tafamidisa i njegovih soli
RU2007110026A (ru) ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
JP2005526011A5 (enExample)
IL217446A (en) Pharmaceutical preparation containing a highly purified active ingredient of 7 - chloro - 5 - hydroxy - 1 - [2 - methyl - 4 - (2 - methylbenzoyl - amino) benzoyl] - 2, 3, 4, 5 - tetrahydro - h - 1 - Benzazepine has a purity of more than 99.5% or its salt, or a drug of its salt
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
HRP20160520T1 (hr) ČVRSTI OBLICI KOJI SADRŽE N-(5-TERC-BUTIL-IZOKSAZOL-3-IL)-N&#39;-{4-[7-(2-MORFOLIN-4-IL-ETOKSI)IMIDAZO[2,1-b]BENZOTIAZOL-2-IL]FENIL}UREJU, NJIHOVI SASTAVI I NJIHOVE UPORABE
JP2014500861A5 (enExample)
JP2010132668A5 (enExample)
JP2011527333A5 (enExample)
HRP20241789T1 (hr) Čvrsti oblici belumosudila i soli belumosudila
MX2013009709A (es) Derivados de heteroarilo como moduladores de nachr alfa 7.
ZA200809820B (en) A novel crystalline form of lamivudine
UA83719C2 (ru) Кристаллическая форма iii агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
JP2013514974A5 (enExample)
JP2020502224A5 (enExample)
JP2008516004A5 (enExample)
JP2015522037A5 (enExample)
JP2008513510A5 (enExample)
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
JP2013520488A5 (enExample)
JP2009040767A5 (enExample)